ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, has realised gross proceeds of approximately £1.5 million on the sale of its entire holding of 9.9 million shares in Incanthera.
Following this transaction, ImmuPharma retains 7.3 million warrants in Incanthera, which have an exercise price of 9.5p and an exercise expiry date of 6 September 2024.